Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
|
|
Immunome Inc. (IMNM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/12/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/12/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/12/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/12/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/12/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 10/12/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 10/12/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/04/2023 |
4
| SIEGALL CLAY B (President and CEO) has filed a Form 4 on Immunome Inc.|
Txns:
| Bought 169,204 shares
@ $5.91, valued at
$1000k
|
|
| 10/04/2023 |
3
| SIEGALL CLAY B (President and CEO) has filed a Form 3 on Immunome Inc. |
| 10/04/2023 |
4
| Turner Bruce (Chief Strategy Officer) has filed a Form 4 on Immunome Inc.|
Txns:
| Bought 42,300 shares
@ $5.91, valued at
$250k
|
|
| 10/04/2023 |
3
| Turner Bruce (Chief Strategy Officer) has filed a Form 3 on Immunome Inc. |
| 10/04/2023 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 60,840 shares
@ $0
Granted 137,725 options to buy
@ $1.35, valued at
$185.9k
|
|
| 10/04/2023 |
8-K
| Entered into consulting agreement|
Docs:
|
"CERTIFICATE OF MERGER MERGING IBIZA MERGER SUB, INC., A DELAWARE CORPORATION WITH AND INTO MORPHIMMUNE INC., A DELAWARE CORPORATION Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware Pursuant to Title 8, Section 251 of the Delaware General Corporation Law , the undersigned corporation executed the following Certificate of Merger: FIRST: The name of the surviving corporation is Morphimmune Inc., a Delaware corporation , and the name of the corporation being merged into this surviving corporation is Ibiza Merger Sub, Inc., a Delaware corporation . SECOND: An Agreement and Plan of Merger and Reorganization, dated June 29, 2023 , by and among Immunome, Inc., a Delaware corporation, Merger Sub and the Company, setting forth the terms and conditions of the m...",
"CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC. It is hereby certified that: FIRST : The name of the corporation is Immunome, Inc. . SECOND : The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by adding new Article IX as follows: IX.",
"CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC.",
"Immunome and Morphimmune Announce Successful Completion of Merger with" |
|
| 10/03/2023 |
4
| RAPP MICHAEL (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 253,806 shares
@ $5.91, valued at
$1.5M
|
|
| 08/25/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Immunome Reports Second Quarter 2023 Financial Results Exton, PA – August 9, 2023 – Immunome, Inc. , a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We believe combining Immunome and Morphimmune’ s technologies represents a major step in our long-term strategy of creating a preeminent oncology therapeutics company,” stated Purnanand Sarma, PhD, President and CEO of Immunome. “Targeted cancer therapies have made great strides in recent years, and the possible synergy between Morphimmune’ s Targeted Effector Platform and Immunome’ s proprietary Discovery Engine presents an..." |
|
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 07/07/2023 |
SC 13D
| MorphImmune Inc. reports a 20% stake in Immunome, Inc. |
| 07/05/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/05/2023 |
8-K
| Investor presentation |
| 06/29/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/29/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/29/2023 |
8-K
| Investor presentation|
Docs:
|
"AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"Schedule A",
"Schedule A",
"Lock-Up Agreement",
"SUBSCRIPTION AGREEMENT",
"EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation , and Clay B. Siegall, Ph.D. . R E C I T A L S WHEREAS, Executive is currently the Chief Executive Officer of Morphimmune Inc., a Delaware corporation , pursuant to a certain Executive Employment Agreement dated as of January 4, 2023 ; WHEREAS, Morphimmune, the Company and Ibiza Merger Sub, Inc., a wholly owned subsidiary of Immunome , are parties to a certain Agreement and Plan of Merger and Reorganization dated as of June 29, 2023 ;    WHEREAS, upon consummation of the merger of Merger Sub into Morphimmune, as contemplated by the Merger Agreement , Morphimmune would become a wholly owned subsidiary of the Company ;   WHERE...",
"Investor Contact",
"CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. and Immunome, Inc. or any person on their behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. No Representations and Warranties This presentation is being distributed solely to qualified institutional buyers and accredited investors with sufficient knowledge and experience in investment, financial and business matters and the capab..." |
|
| 06/12/2023 |
4
| RAPP MICHAEL (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 6,500 options to buy
@ $4.84, valued at
$31.5k
|
|
| 06/12/2023 |
4
| Stoneman Sandra G. (General Counsel and CLO) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 56,000 options to buy
@ $4.84, valued at
$271k
|
|
| 06/12/2023 |
4
| Roche Corleen M. (CFO) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 58,000 options to buy
@ $4.84, valued at
$280.7k
|
|
| 06/12/2023 |
4
| ROBINSON MATTHEW K (Chief Technology Officer) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 58,000 options to buy
@ $4.84, valued at
$280.7k
|
|
| 06/12/2023 |
4
| Sarma Purnanand D (President and CEO) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 166,500 options to buy
@ $4.84, valued at
$805.9k
|
|
| 06/12/2023 |
4
| Lefenfeld Michael (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 6,500 options to buy
@ $4.84, valued at
$31.5k
|
|
| 06/12/2023 |
4
| LAMATTINA JOHN L (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 6,500 options to buy
@ $4.84, valued at
$31.5k
|
|
| 06/12/2023 |
4
| BARON RICHARD A (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 6,500 options to buy
@ $4.84, valued at
$31.5k
|
|
| 06/12/2023 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 6,500 options to buy
@ $4.84, valued at
$31.5k
|
|
|
|
|